To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part II

Posted by Nelson N. Stone, MD | Nov 2017

Nelson N. Stone, MD, Icahn School of Medicine at Mount Sinai, New York, New York, discusses the advantages of mapping biopsies compared to MRI for prostate cancer.

Keywords: mapping biopsies, MRI, prostate cancer

About The Author

Nelson N. Stone, MD

Nelson N. Stone, MD, is Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and at the Derald H. Ruttenberg Cancer Center at Mount Sinai. He also serves as CEO of 3D Biopsy, LLC. Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a Residency in General Surgery in 1981 at the University of Maryland, followed by a Residency in Urology at the University of Maryland. He then completed a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center and a Research Fellowship in Biochemical Endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elmhurst Hospital from 1989-1996. Dr. Stone has founded several medical companies and serves on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 400 articles, abstracts, and book chapters, primarily on prostate cancer. He invented the real-time technique for prostate seed implantation in 1990 and has trained more than 5,000 physicians worldwide on prostate brachytherapy through his company ProSeed. His company, 3DBiopsy, Inc., is developing variable length biopsy devices, mapping software, and an integrated pathology system.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Exercise & Wellness

Join the GRU Community

Watch, Listen, Learn, and Engage with Experts in the Urology Community.

To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part II

About The Author

Nelson N. Stone, MD

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Join the GRU Community

You have Successfully Subscribed!

To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part II

About The Author

Nelson N. Stone, MD

Related Posts

Imaging of Metastatic Prostate Cancer: Whole Body MRI and Novel PET Techniques

Prevention, Screening, and Genomic Markers Panel Discussion

Radical Prostatectomy: Management of the Primary From Localized to Oligometastatic Disease

Prostate Inflammation and Prostate Cancer: What do I need to know?

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

Join the GRU Community

You have Successfully Subscribed!

– Account Dashboard
– Your Courses